Jasper Hellweg
Stock Analyst at Argus Research
(3.50)
# 731
Out of 4,818 analysts
89
Total ratings
52.11%
Success rate
17.37%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Downgrades: Hold | n/a | $118.17 | - | 4 | Apr 4, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $293.46 | +36.30% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $76.36 | +96.45% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $53.02 | +13.16% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $587.85 | +99.03% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $492.42 | +11.69% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $68.51 | +24.07% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $61.29 | +103.95% | 1 | Feb 1, 2024 | |
| MRNA Moderna | Maintains: Buy | $160 → $140 | $26.54 | +427.51% | 4 | Sep 13, 2023 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $176.95 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $200 | $150.91 | +32.53% | 6 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $14.29 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $147.06 | +97.20% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $120.49 | -17.01% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $224.40 | +31.46% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.01 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $173.78 | -22.32% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $29.65 | - | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $24.74 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $249.31 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $106.00 | - | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $42.27 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $336.24 | -53.90% | 3 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $217.13 | -58.55% | 1 | Sep 19, 2018 |
Biogen
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $118.17
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $293.46
Upside: +36.30%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $76.36
Upside: +96.45%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $53.02
Upside: +13.16%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $587.85
Upside: +99.03%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $492.42
Upside: +11.69%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $68.51
Upside: +24.07%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $61.29
Upside: +103.95%
Moderna
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $26.54
Upside: +427.51%
AbbVie
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $176.95
Upside: -
Jun 17, 2022
Maintains: Buy
Price Target: $225 → $200
Current: $150.91
Upside: +32.53%
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $14.29
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $147.06
Upside: +97.20%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $120.49
Upside: -17.01%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $224.40
Upside: +31.46%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $5.01
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $173.78
Upside: -22.32%
Sep 4, 2020
Downgrades: Hold
Price Target: n/a
Current: $29.65
Upside: -
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $24.74
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $249.31
Upside: -
Mar 24, 2020
Downgrades: Hold
Price Target: n/a
Current: $106.00
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $42.27
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $336.24
Upside: -53.90%
Sep 19, 2018
Maintains: Buy
Price Target: $85 → $90
Current: $217.13
Upside: -58.55%